Compare · ADMA vs ARGX
ADMA vs ARGX
Side-by-side comparison of ADMA Biologics Inc (ADMA) and argenx SE (ARGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADMA and ARGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $63.27B, about 29.1x ADMA ($2.18B).
- ARGX has been more active in the news (11 items in the past 4 weeks vs 5 for ADMA).
- ARGX has more recent analyst coverage (25 ratings vs 10 for ADMA).
- Company
- ADMA Biologics Inc
- argenx SE
- Price
- -
- -
- Market cap
- $2.18B
- $63.27B
- 1M return
- +14.67%
- -
- 1Y return
- -43.07%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 5
- 11
- Recent ratings
- 10
- 25
ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ADMA
- Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
- SEC Form SCHEDULE 13G filed by ADMA Biologics Inc
- SEC Form 10-Q filed by ADMA Biologics Inc
- ADMA Biologics Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
- ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026
- COO and SVP, Compliance Kestenberg-Messina Kaitlin M. covered exercise/tax liability with 3,177 shares, decreasing direct ownership by 0.71% to 443,061 units (SEC Form 4) (withholding obligation)
- CFO and Treasurer Kohler Terry was granted 85,130 shares, increasing direct ownership by 147% to 143,149 units (SEC Form 4)
- Raymond James resumed coverage on ADMA Biologics with a new price target
- ADMA Biologics Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest ARGX
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
- SEC Form SC TO-T filed by argenx SE
- Guggenheim resumed coverage on argenx with a new price target
- SEC Form 6-K filed by argenx SE